The beginning of the perioperative immunotherapy era in early-stage non-small cell lung cancer.

Transl Lung Cancer Res · 2023 · PMC10713273 · PMID 38090512

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

For now, results from the first interim OS analysis indicates a positive trend favoring atezolizumab in the PD-L1 ≥50% of TC in stages II–IIIA (HR =0.43; 95% CI: 0.24–0.78) ( 18 ).

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.